Cargando…
Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment
Transthyretin cardiomyopathy (ATTR‐CM) is an under‐recognized cause of heart failure, but it has received increasing attention due to the availability of treatment options. We present a case of hereditary transthyretin cardiomyopathy (A97S, an under‐represented variant in current clinical studies) w...
Autores principales: | Wu, Yuan‐Kun (Aden), Tsai, Cheng‐Hsuan, Su, Mao‐Yuan, Chao, Chi‐Chao, Cheng, Mei‐Fang, Shun, Chia‐Tung, Hsieh, Sung‐Tsang, Lin, Yen‐Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773766/ https://www.ncbi.nlm.nih.gov/pubmed/36128649 http://dx.doi.org/10.1002/ehf2.14165 |
Ejemplares similares
-
Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
por: Tsai, Cheng-Hsuan, et al.
Publicado: (2023) -
Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022) -
Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis
por: Nakamura, Makiko, et al.
Publicado: (2023) -
A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
por: Waddington Cruz, Márcia, et al.
Publicado: (2015) -
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)